0001437749-26-017397
SEC filingNRx Pharmaceuticals generated first significant revenue of $1.1M from Dura patient services amid ongoing operating losses of $4.7M, reflecting transition from pure R&D to integrated clinical operations with persistent funding needs.
NRx Pharmaceuticals posted its first meaningful revenue of $1.1M in Q1 2026, entirely from net patient service revenue generated by Dura Therapeutics following its September 2025 acquisition. This milestone reflects partial-quarter operations across clinical services, with management attributing the topline to initial integration efforts of HOPE Therapeutics, now operating five Florida locations and targeting eight by Q2 end. Gross profit stood at $437K, delivering a 40.9% margin that underscores effective pricing on early patient volumes despite the nascent stage. Investors should note management's outlook for revenue increases as Dura's operations fully integrate, clinical capacity expands, patient volumes grow, and service lines broaden under company ownership. However, scalability depends on successful clinic expansion and clinical activity ramp-up.
Net income showed a $1.4M loss with diluted EPS of -$0.04, improved from deeper prior losses through non-cash and non-operating adjustments. While specific drivers like warrant gains were audit-removed, the narrowing reflects financial engineering supporting core operations. Management's commentary emphasizes historical minimal revenues and persistent losses since inception, with expectations of significant operating deficits continuing. This underscores why revenue diversification via Dura/HOPE is critical, yet insufficient alone to achieve near-term profitability.
Net cash used in operating activities totaled $4.3M, highlighting cash burn as revenue partially offsets expense growth but falls short of breakeven. Liquidity remains a focal point, with the company flagging going concern doubts and reliance on external financing. Management anticipates cost pressures scaling with expansion, reinforcing the need for disciplined capital allocation amid clinic buildout and trial progression. Investors should track cash management as revenue trajectory and cost discipline determine funding runway.